Sample Report
This Is What a Medication Safety Report Looks Like
Scroll through a complete sample report built from fictional DNA data. Your report follows the same structure — personalized to your genetics.
What's Inside Your Report
Every Medication Safety Report includes these sections, personalized to your DNA — covering genes like CYP2C19 and CYP2D6
Risk Snapshot
Your overall medication genetic risk — High, Moderate, or Low — with a clear next step on the first page.
90-Second Summary
Top findings in plain language with affected medications and what to discuss with your provider.
Clinician Pocket Summary
A one-page clinical reference your doctor or pharmacist can review in under 60 seconds.
Detailed Gene Findings
Full analysis of each gene with your diplotype, phenotype, affected drugs, and CPIC-backed recommendations.
Complete Gene Panel
All 13 pharmacogenes tested with results — including the ones that came back normal.
Severe Drug Reaction Risk (HLA-B)
Screening for HLA-B variants linked to life-threatening drug reactions — abacavir, carbamazepine, and allopurinol.
Medication Checklist
Every medication checked against your genetics, with brand names you recognize and actionable/normal status.
Limitations & Glossary
Transparent disclosure of what this report can and cannot tell you, plus definitions of key terms.
Medication Safety Report — Full Sample
Medication Safety Report
Pharmacogenomic Analysis — DecodeMyBio
Report Date: February 12, 2026
Report ID: DMB-2026-SAMPLE
Your genetics suggest 1 medication interaction requiring attention and 3 areas to review with your provider.
Your body may not fully activate clopidogrel (Plavix), a common blood thinner used after cardiac events. Your body processes certain pain medications differently, which may reduce their effectiveness. Your risk of statin-related muscle pain is elevated compared to most people. This report identifies which specific medications are affected and what to discuss with your healthcare provider.
Real-World Implications
Your blood thinner may be less effective
Affects: clopidogrel (Plavix)
Clopidogrel (Plavix) relies on CYP2C19 to activate it. Your genetics indicate moderately reduced activation, which may reduce its protective effect compared to normal metabolizers.
Why this happens
Your CYP2C19 result is *1/*2 (Intermediate Metabolizer).
What clinicians sometimes consider
- Clinicians sometimes consider alternative antiplatelet agents for intermediate metabolizers, especially for high-risk cardiac procedures
Your pain medication may provide less relief
Affects: codeine (Tylenol #3), tramadol (Ultram)
Your body converts codeine and tramadol into their active forms more slowly than most people. These medications may provide reduced pain relief at standard doses.
Full analysis and clinician considerations in your report
Your statin muscle-pain risk is elevated
Affects: simvastatin (Zocor), atorvastatin (Lipitor), rosuvastatin (Crestor)
You carry a variant in SLCO1B1 that reduces statin transport into the liver. This increases circulating statin levels, raising the risk of muscle pain (myopathy) — the most common statin side effect.
Full analysis and clinician considerations in your report
Your antidepressant dose may need fine-tuning
Affects: paroxetine (Paxil), fluoxetine (Prozac), venlafaxine (Effexor), amitriptyline (Elavil)
Your body clears certain antidepressants slightly more slowly than most people. This may result in modestly higher drug levels, which could affect both effectiveness and side effect profile.
Full analysis and clinician considerations in your report
3 additional scenarios with full explanations and clinical considerations in your report
Risk Snapshot
Moderate Risk
Overall Medication Genetic Risk
0
Significant
3
Moderate
13
Genes Tested
Next step: Share this report with your prescriber before starting or changing any of the medications listed below.
90-Second Summary
Genes with findings
3 of 13
CYP2C19, CYP2D6, SLCO1B1
Medications affected
12+
Including clopidogrel, codeine, simvastatin
Risk level
Moderate
No significant findings; 3 moderate
Your results show altered enzyme activity in 3 pharmacogenes. This means your body may process certain medications differently than expected. None of your findings are classified as significant risk, but each one may warrant a dosing adjustment or alternative medication.
When This Report Matters
- ●You are prescribed clopidogrel (Plavix) after a cardiac stent — your CYP2C19 result means the standard dose may be less effective.
- ●Your doctor prescribes codeine for pain relief — your CYP2D6 result suggests reduced conversion to the active form.
- ●You start simvastatin (Zocor) for cholesterol — your SLCO1B1 result indicates higher risk of muscle-related side effects at standard doses.
Clinician Pocket Summary
One-Page Clinical Reference
| Gene | Diplotype | Phenotype | Activity | Key Medications | Suggested Action |
|---|---|---|---|---|---|
| CYP2C19 | *1/*2 | Intermediate Metabolizer | 1.0 | Clopidogrel, escitalopram, sertraline | Consider alternative antiplatelet; adjust SSRI if needed |
| CYP2D6 | *1/*4 | Intermediate Metabolizer | 1.0 | Codeine, tramadol, amitriptyline | Avoid codeine; consider alternative analgesic |
| SLCO1B1 | *1A/*5 | Decreased Function | N/A | Simvastatin, atorvastatin | Use lower simvastatin dose or alternative statin |
Detailed Gene Findings
CYP2C19
*1/*2 — Intermediate Metabolizer
You carry one reduced-function CYP2C19 allele. This enzyme activates clopidogrel and metabolizes several SSRIs. With intermediate metabolizer status, you may have reduced activation of clopidogrel and altered SSRI levels.
Affected Medications
Clinical Recommendation
CPIC recommends considering an alternative antiplatelet agent (e.g., prasugrel or ticagrelor) for CYP2C19 intermediate metabolizers requiring antiplatelet therapy. For SSRIs, consider dose adjustment or therapeutic drug monitoring.
CYP2D6
*1/*4 — Intermediate Metabolizer
You carry one non-functional CYP2D6 allele.
Full finding with affected medications and CPIC recommendation available in your report
SLCO1B1
*1A/*5 — Decreased Function
You carry one reduced-function SLCO1B1 allele (rs4149056 TC).
Full finding with affected medications and CPIC recommendation available in your report
2 additional findings with affected medications and CPIC recommendations in your personalized report
Medication Checklist
Medications checked against your genetic profile. Actionable items have a gene-drug interaction that may affect dosing or drug choice.
Clopidogrel (Plavix)
Escitalopram (Lexapro)
Citalopram (Celexa)
Sertraline (Zoloft)
Codeine (Tylenol #3)
Tramadol (Ultram)
+8 more medications checked in your full report — 48 total
Other Genes Tested
10 additional genes were analyzed and returned normal or expected results. No dosing changes indicated. Full breakdown included in your report.
Severe Drug Reaction Risk (HLA-B)
Screening for HLA-B variants linked to severe drug hypersensitivity reactions. Based on tag SNP proxies, not clinical HLA typing.
Affected medication: abacavir (Ziagen)
No HLA-B*57:01 risk allele was detected via tag SNP screening. This suggests a lower risk of abacavir hypersensitivity. This result is based on a tag SNP proxy and does not replace clinical HLA typing.
Affected medication: carbamazepine (Tegretol)
No HLA-B*15:02 risk allele was detected via tag SNP screening. This suggests a lower risk of carbamazepine-induced SJS/TEN. This result is based on a tag SNP proxy and does not replace clinical HLA typing.
Affected medication: allopurinol (Zyloprim)
No HLA-B*58:01 risk allele was detected via tag SNP screening. This suggests a lower risk of allopurinol hypersensitivity. This result is based on a tag SNP proxy and does not replace clinical HLA typing.
Limitations
- •Consumer genotyping arrays test a subset of known pharmacogenomic variants. Rare or novel alleles may not be detected.
- •Structural variants (e.g., CYP2D6 gene deletions or duplications) cannot be reliably determined from array data.
- •This report does not account for phenoconversion — when concomitant medications inhibit or induce enzyme activity, effectively changing your metabolizer status.
- •Allele frequency databases may underrepresent certain populations, potentially affecting phenotype assignment accuracy.
- •Drug response depends on multiple factors beyond genetics, including age, weight, kidney/liver function, diet, and other medications.
This is a sample report generated with fictional data for demonstration purposes. Your actual report will reflect your personal genetic results.
Get your personalized report
Upload your 23andMe or AncestryDNA raw data. Your Medication Safety Report is $49 — one-time, no subscription.
Get Your Personalized Report — $49Free Upload vs. Medication Safety Report
Everyone gets free trait insights after uploading. The full report goes further — turning raw genetic data into medication-specific guidance.
Free with upload
- 9 trait insights (caffeine, lactose, etc.)
- Metabolizer status for key genes
- Which medications are affected
- CPIC clinical recommendations
- Clinician pocket summary
- HLA drug reaction screening
Medication Safety Report
$49- Everything in free, plus:
- 48 medications checked against your DNA
- Per-drug CPIC clinical recommendations
- Shareable clinician pocket summary
- HLA drug reaction screening (3 alleles)
- Risk snapshot and 90-second summary
Clinical-Grade Insights from DNA Data You Already Have
DecodeMyBio reports start at $49 using raw data from 23andMe or AncestryDNA you've already paid for. Pharmacogenomic testing ordered through healthcare providers — such as GeneSight — typically costs several hundred to over a thousand dollars, often requires a new sample, and may not be covered by insurance.
Both approaches reference CPIC clinical guidelines. The difference: you already have the data — we just interpret it.
Built on CPIC Guidelines
Every finding cites evidence from the Clinical Pharmacogenetics Implementation Consortium (CPIC) — the same guidelines used by hospitals and pharmacies worldwide. Only Level A (strong) and Level B (moderate) evidence is included.
For educational and informational purposes only. Not a substitute for clinical pharmacogenomic testing or medical advice. See our limitations page for details.
Explore Other Sample Reports
Six clinically-grounded reports, each covering a different aspect of your genetic health.
Nutrition
Nutrition & Methylation Report
MTHFR, folate, B12, and vitamin D variants with priority dashboard and food-first action plan.
View sample →Psychiatric
Psychiatric Medication Report
Antidepressants, ADHD meds, and mood stabilizers mapped to CYP2D6 + CYP2C19 with condition-based grouping.
View sample →Cannabis & CBD
Cannabis & CBD Report
THC and CBD metabolism, gene-gene side effect risk, and smoked cannabis drug interactions.
View sample →Pain & Anesthesia
Pain & Anesthesia Report
Opioid response, pain sensitivity, and anesthesia considerations based on your genetics.
View sample →Celiac Screening
Celiac & Gluten Screening
Rule out celiac disease with HLA-DQ2 and HLA-DQ8 genetic screening. Results in minutes.
View sample →Ready to See Your Results?
Upload your 23andMe or AncestryDNA raw data. Your personalized Medication Safety Report is $49 — one-time, no subscription.